



**UvA-DARE (Digital Academic Repository)**

**Prefrontal involvement related to cognitive impairment in progressive muscular atrophy**

Raaphorst, J.; van Tol, M.J.; Groot, P.F.C.; Altena, E.; van der Werf, Y.D.; Majoie, C.B.; van der Kooi, A.J.; van den Berg, L.H.; Schmand, B.A.; de Visser, M.; Veltman, D.J.

*Published in:*  
Neurology

*DOI:*  
[10.1212/WNL.0000000000000745](https://doi.org/10.1212/WNL.0000000000000745)

[Link to publication](#)

*Citation for published version (APA):*

Raaphorst, J., van Tol, M. J., Groot, P. F. C., Altena, E., van der Werf, Y. D., Majoie, C. B., ... Veltman, D. J. (2014). Prefrontal involvement related to cognitive impairment in progressive muscular atrophy. *Neurology*, 83(9), 818-825. DOI: 10.1212/WNL.0000000000000745

**General rights**

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

**Disclaimer/Complaints regulations**

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: <http://uba.uva.nl/en/contact>, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

# Prefrontal involvement related to cognitive impairment in progressive muscular atrophy

Joost Raaphorst, MD  
Marie-José van Tol, PhD  
Paul F.C. Groot, PhD  
Ellemarije Altena, PhD  
Ysbrand D. van der Werf,  
PhD  
Charles B. Majoie, MD,  
PhD  
Anneke J. van der Kooi,  
MD, PhD  
Leonard H. van den Berg,  
MD, PhD  
Ben Schmand, PhD  
Marianne de Visser, MD,  
PhD  
Dick J. Veltman, MD,  
PhD

Correspondence to  
Dr. Raaphorst:  
joost.raaphorst@radboudumc.nl

## ABSTRACT

**Objective:** To examine brain activation patterns during verbal fluency performance in patients with progressive muscular atrophy (PMA) and amyotrophic lateral sclerosis (ALS).

**Methods:** fMRI was used to examine the blood oxygen level-dependent response during letter and category fluency performance in 18 patients with PMA, 21 patients with ALS, and 17 healthy control subjects, matched for age and education. fMRI results are reported at  $p < 0.05$ , family-wise error (FWE)-corrected for multiple comparisons. We analyzed effects of performance, age-related white matter changes (ARWMC), and regional brain volumes; all participants underwent neuropsychological investigation.

**Results:** Disease duration of patients with PMA (mean 26.0 months, SD 13.6) and ALS (22.2 months, SD 11.4) was comparable. Patients with PMA and ALS had mild to moderate disease severity and showed impaired letter fluency compared with controls. Between-group analysis showed a main effect of group in the left inferior frontal gyrus (IFG, Brodmann area 45) during letter fluency, which was unaffected by performance, ARWMC, and IFG volume: patients with PMA showed lower activation than controls but higher than that of patients with ALS (ALS < PMA < healthy controls;  $p_{\text{FWE}} = 0.035$ ;  $z$  score 4.11; cluster size = 11). A more caudal region in the IFG showed lower activation in patients with PMA than controls during letter fluency performance (post hoc test;  $p_{\text{FWE}} = 0.026$ ). No activation differences were observed during the category fluency task.

**Conclusion:** Prefrontal activation abnormalities are related to an important clinical measure of executive dysfunction in patients with motor neuron disease with and without upper motor neuron signs. *Neurology*® 2014;83:818-825

## GLOSSARY

**ALS** = amyotrophic lateral sclerosis; **ALSFRS-R** = Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised; **ARWMC** = age-related white matter changes; **BA** = Brodmann area; **BOLD** = blood oxygen level-dependent; **DSM-IV** = *Diagnostic and Statistical Manual of Mental Disorders, 4th edition*; **FWE** = family-wise error; **HC** = healthy control; **IFG** = inferior frontal gyrus; **MND** = motor neuron disease; **PFC** = prefrontal cortex; **PMA** = progressive muscular atrophy; **UMN** = upper motor neuron.

Motor neuron disease (MND) encompasses amyotrophic lateral sclerosis (ALS) and progressive muscular atrophy (PMA; only lower motor neuron clinical features). Approximately 30% to 50% of patients with ALS have cognitive impairments, which are correlated to impaired decision-making (e.g., feeding tube insertion and noninvasive ventilation) and decreased survival.<sup>1-3</sup> One of the most consistently reported cognitive abnormalities is letter fluency impairment, which is used as a clinical screening measure and has been related to reduced activation in prefrontal and temporal brain regions on fMRI and PET.<sup>4-7</sup> These functional imaging findings have been corroborated by studies relating abnormal regional brain metabolites and gray matter densities to fluency impairment in ALS.<sup>8,9</sup>

## Supplemental data at Neurology.org

From the Departments of Neurology (J.R., A.J.v.d.K., B.S., M.d.V.) and Radiology (P.F.C.G., C.B.M.), Academic Medical Center, University of Amsterdam; Departments of Psychiatry (D.J.V.) and Anatomy and Neurosciences (Y.D.v.d.W.), VU University Medical Centre, Amsterdam; Department of Psychology (B.S.), University of Amsterdam; Neuroimaging Center (M.-J.v.T.), University Medical Center Groningen, University of Groningen; Brain Center Rudolf Magnus Institute of Neuroscience (L.H.v.d.B.), Department of Neurology, University Medical Center Utrecht; Netherlands Institute for Neuroscience (E.A., Y.D.v.d.W.), an Institute of the Royal Netherlands Academy of Arts and Sciences, Amsterdam; Department of Neurology (J.R.), Radboud University Medical Center Nijmegen, the Netherlands; and Department of Clinical Neurosciences (E.A.), University of Cambridge, UK.

Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

In PMA, nonmotor cerebral involvement is disputed: no abnormalities have been shown on cognitive testing, regional cerebral blood flow imaging, or magnetic resonance spectroscopy of the prefrontal cortex (PFC) in patients with PMA.<sup>8,10,11</sup> However, we previously found fluency deficits in patients with PMA and reduced fractional anisotropy in the white matter of the PFC in another cohort of patients with PMA, suggesting nonmotor cerebral involvement, although neuropsychological assessment was not performed in the latter study.<sup>12,13</sup>

The presence of nonmotor cerebral involvement in PMA would add to clinical, genetic, and pathologic findings, which support the view that a proportion of patients with PMA should be regarded as having ALS.<sup>14–16</sup> The latter is important for future revisions of diagnostic criteria of MND (should PMA with cognitive impairments be regarded as ALS?) and eligibility for therapeutic trials.<sup>17</sup>

The aim of this study was to examine whether nonmotor cerebral involvement in PMA could be established using fMRI. We hypothesized that patients with PMA show nonmotor cerebral involvement in frontal and temporal brain regions previously associated with fluency performance in ALS.

**METHODS Participants.** Patients were recruited from tertiary referral centers for MND in Amsterdam (Academic Medical Center) and Utrecht (University Medical Center). Spouses and friends participated as healthy controls (HCs), matched for education and age. The patients with ALS could be classified as probable or definite ALS (revised El Escorial criteria).<sup>13,17</sup> Patients with PMA fulfilled the criteria as earlier described<sup>13,14</sup>: (1) diagnosed within 5 years, (2) clinical and electrophysiologic evidence of lower motor neuron involvement in 2 or more regions (bulbar, cervical, thoracic, and lumbosacral), (3) no conduction blocks on extensive nerve conduction studies, and (4) no clinical upper motor neuron (UMN) signs and symptoms.<sup>13,14</sup> We excluded patients and controls if they had preexistent frontotemporal dementia or another dementia according to consensus criteria (*DSM-IV* and Lund-Manchester criteria<sup>18</sup>), a history of another neurologic disorder associated with cognitive impairment, a vital capacity lower than 70% of the predicted value, and severe dysarthria.<sup>13</sup> Patients had to be able to push a button with the index finger of the right hand without difficulty, had to be free of psychoactive medication, and had to speak Dutch fluently.<sup>13</sup>

Before this study, one comparable fMRI study in ALS had been performed precluding a valid power analysis. Moreover, for fMRI, generally accepted methods for power calculation are not yet available. Methodologic studies with simulated and real data have shown that group sizes of 12 to 20 participants are sufficient for detecting small to medium effects.<sup>19,20</sup>

**Standard protocol approvals and patient consents.** This study was approved by the medical ethical committees of

the hospitals. Written informed consent was obtained from all participants.

**Clinical assessment.** We used the revised ALS Functional Rating Scale (ALSFRS-R) to assess the functional status of the patients.<sup>21</sup> Further assessments included site of onset (bulbar or limb); bulbar involvement (a score <4 on one or more of the bulbar items of the ALSFRS-R); UMN score (sum score of myotatic and pathologic UMN reflexes and pseudobulbar affect; range 0–48; based on Ellis et al.<sup>22</sup> and described earlier<sup>13</sup>); disease duration (months between first sign of muscle weakness and the MRI scan); and the number of years of formal education.

**Neuropsychological assessment.** Patients and controls underwent a comprehensive neuropsychological examination in an outpatient clinic near the patient's home, including rest periods if needed. The tests were administered in a fixed order and covered premorbid intellectual ability, global cognitive impairment, executive functions, memory, language, attention and working memory, psychomotor speed, and visuospatial functions as described earlier (tests and adjustments for motor and speech impairment are described in appendix e-1 on the *Neurology*<sup>®</sup> Web site at [Neurology.org](http://Neurology.org)).<sup>13</sup> We used 2 fluency tests: letter fluency (Controlled Oral Word Association Test, using the letters K, O, and M) and category fluency (animals and supermarket items).<sup>13,23,24</sup> We rated anxiety and depression using the Hospital Anxiety and Depression Scale.<sup>13,25</sup>

**Statistical analysis of neuropsychological test results.** Group differences of neuropsychological measures (PMA vs ALS and controls) were analyzed using analysis of variance,  $\chi^2$ /Fisher exact test, or Student *t* test, where appropriate. Two-sided *p* values <0.05 were considered significant. Data were analyzed with SPSS version 21 (IBM Corp., Armonk, NY).

**MRI.** Patients and controls underwent an MRI scan within 4 weeks of the neuropsychological examination, i.e., not on the same day to prevent fatigue effects. Images were acquired on a Philips Intera 3T MRI scanner (Philips Medical Systems, Best, the Netherlands) with a SENSE-6 channel head coil for radiofrequency transmission and reception.

**fMRI task.** The letter and category fluency tasks used here have shown robust left prefrontal activation in HCs with a mean age of 60 years (SD 8.2) in a previous study.<sup>26</sup> Three letter fluency blocks and 3 category fluency blocks, of 30 seconds each, alternated with 7 blocks of a baseline task (counting backward) of 15 seconds each. During the fluency blocks, participants had to press a button for every covertly generated word (without pronouncing the word, to reduce movement artifacts and not to burden patients with bulbar involvement) either starting with the letter or belonging to the category. Participants were informed about the task before entering the scanner and examples of each of both tasks, not used in the scanner or in the neuropsychological investigation, were given. Patients were instructed not to produce names and consecutive words starting with the same prefix and to keep their eyes open during the experimental and baseline conditions. During the baseline task, participants pressed a button for every number covertly counted backward. Performance was measured as the total number of button presses registered through 2 magnet-compatible button boxes. To reduce possible retest effects, we used parallel versions of the fluency tests with the letters D, A, and T and categories “vegetables/fruit,” “tools,” and “occupations.”<sup>27,28</sup>

**Structural MRI acquisition and analysis.** For each subject, a 3-dimensional, gradient-echo, T1-weighted image and a T2-weighted structural image were acquired (appendix e-2). We

**Table 1** Demographic and clinical characteristics of patients with PMA and ALS and control subjects

Characteristic	PMA (n = 18)	ALS (n = 21)	HC (n = 17)	p Value
Sex, M/F	13/5	15/6	10/7	0.481
Age, y	60.4 (9.7)	60.3 (10.2)	59.0 (10.8)	0.904
Handedness, R/L	16/2	21/0	16/1	0.301
Premorbid IQ	100.8 (16.9)	104.4 (16.4)	106.2 (16.8)	0.656
Education, y	14.4 (3.1)	14.1 (2.6)	13.9 (2.1)	0.843
HADS anxiety <sup>a</sup>	4.3 (2.5), 0%	3.9 (3.0), 0%	4.7 (3.2), 5.9%	0.671
HADS depression <sup>a</sup>	3.9 (2.6), 0%	4.1 (3.6), 9.5%	3.5 (4.1), 11.8%	0.840
HADS total	8.2 (4.8)	8.2 (6.8)	8.0 (6.2)	0.994
Disease duration, mo	26.0 (13.6)	22.2 (11.4)	—	0.353
Bulbar onset, n (%)	0 (0)	5 (23.8)	—	0.050 <sup>b</sup>
Bulbar region affected, <sup>c</sup> n (%)	4 (22.2)	12 (57.1)	—	0.037 <sup>b</sup>
Familial/sporadic	1/17	4/17	—	0.355
ALSFRS-R <sup>d</sup>	41.5 (3.7)	40.0 (4.9)	—	0.298
Upper motor neuron score <sup>e</sup>	16.0 (6.8)	33.3 (7.1)	—	<0.0001 <sup>b</sup>
White matter changes score <sup>f</sup>	1.5 (1.4)	2.3 (2.3)	1.2 (1.3)	0.137

Abbreviations: ALS = amyotrophic lateral sclerosis; ALSFRS-R = Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised; HADS = Hospital Anxiety and Depression Scale; HC = healthy control; PMA = progressive muscular atrophy. Values are mean (SD), unless stated otherwise.

<sup>a</sup>For HADS subscales, the proportions of subjects with scores above the cutoff (>10) for moderate or severe disturbances are given ( $p = 0.320$  for anxiety and  $0.368$  for depression).

<sup>b</sup> $p$  Values <0.05.

<sup>c</sup>Bulbar region affected = score below 4 on one of the bulbar items of the ALSFRS-R.

<sup>d</sup>Maximum score = 48; indicates no handicap.

<sup>e</sup>Maximum score = 48; normal score is 16.

<sup>f</sup>Age-related white matter changes scale (maximum score = 30; indicates severe white matter changes).

used T1-weighted scans for a preprocessing step of the fMRI analysis and to calculate mean volumes of structures containing significant activation effects—scaled for total gray matter volume. T2-weighted images were used to rate white matter lesions according to the age-related white matter changes (ARWMC) scale.

**fMRI acquisition and analysis.** For each subject, 250 echo planar imaging volumes sensitive to the blood oxygen level-dependent (BOLD) effect were obtained, entailing a T2-weighted, gradient-echo sequence (repetition time 2,300 milliseconds, echo time 30.0 milliseconds, flip angle 80°) using axial whole-brain acquisition, with an interleaved slice acquisition order. The echo planar imaging volumes were acquired at 40 slices (3-mm thickness, no gap); matrix size  $96 \times 96$  voxels; in-plane resolution  $2.29 \times 2.29$  mm.

fMRI data were preprocessed and analyzed (appendix e-2) using Statistical Parametric Mapping software (SPM8) implemented in MATLAB version 7.8.0 (The MathWorks Inc., Natick, MA).

Following the summary statistics approach, contrast images were calculated per subject on a voxel-by-voxel basis and entered into second-level analyses for between-group (PMA, ALS, HC) comparisons (analysis of covariance) with performance as covariate (set to interact with factor “group” to allow further investigation of performance effects within groups). The main effect of the fMRI task is reported at a threshold of  $p < 0.05$  whole brain corrected for family-wise error (FWE).

Age and education were added to the model to account for variance related to these factors. To investigate an effect of white matter changes and regional volume, in addition, we added the ARWMC scores and mean volumes of the structures containing significant activation effects as covariates.

For the between-group comparisons, we restricted the area for correction to include the left inferior frontal gyrus (IFG), left middle frontal gyrus (dorsolateral PFC), left middle temporal gyrus, and bilateral anterior cingulate cortex as regions of interest, based on our hypothesis and their known involvement in letter fluency processing in ALS.<sup>6,26,29</sup> We constructed a composite mask with the aid of the Anatomical Automatic Labeling implemented in the WFU Pick-Atlas using the following labels: Frontal\_Inf\_Tri\_L, Frontal\_Inf\_Oper\_L, Frontal\_Mid\_L, Temporal\_Mid\_L, Cingulum\_Ant\_L, and Cingulum\_Ant\_R.<sup>30</sup> Main effects of group ( $F$  test) and post hoc  $t$  tests are reported at  $p < 0.05$ , FWE-corrected for the extent of this composite mask.

A similar approach for category fluency analyses is described in appendix e-2.

**RESULTS** MRI scans of 18 patients with PMA, 21 patients with ALS, and 17 HCs were analyzed. Thirty-six participants (64.2%) underwent the neuropsychological investigation first; the other 20 participants underwent MRI scanning first. The order of the investigations (neuropsychological investigation and MRI) did not differ among PMA, ALS, and HC groups ( $p = 0.35$ ). Three left-handed participants were included. UMN score, site of onset, and bulbar involvement differed between ALS and PMA patients; none of the demographic and other clinical characteristics differed significantly between the groups (table 1).

**Table 2** Neuropsychological examination: Letter and category fluency test results in patients and control subjects (ANOVA, main effect of group)

Fluency	Groups			p Value
	PMA (n = 18)	ALS (n = 21)	HC (n = 17)	
<b>Letter</b>				
Score	35.5 (11.4) <sup>a</sup>	35.3 (11.9) <sup>b</sup>	43.7 (9.9)	0.048 <sup>c</sup>
Perseverations	1 (0-4)	0 (0-10)	0 (0-3)	0.771
Motor speed corr.	4.4 (2.0)	4.3 (1.8)	3.3 (0.8)	0.070
<b>Category</b>				
Score	44.7 (13.5)	43.3 (11.9)	51.5 (10.8)	0.104
Perseverations	0 (0-4)	0 (0-4)	0 (0-2)	0.305
Motor speed corr.	2.1 (1.4)	1.9 (0.8)	1.5 (0.5)	0.132

Abbreviations: ALS = amyotrophic lateral sclerosis; ANOVA = analysis of variance; corr. = corrected; HC = healthy control; PMA = progressive muscular atrophy. Values are mean (SD) or median (range); score = number of words in 3 (letter) or 2 (category) trials of 1 minute. Results of other neuropsychological tests and description of motor speed corrected are in appendix e-1.


<sup>a</sup>PMA vs HC:  $p = 0.033$ .

<sup>b</sup>ALS vs HC:  $p = 0.027$  (Student *t* test).

<sup>c</sup> $p$  Value <0.05 (ANOVA).

**Neuropsychological test performance.** The PMA, ALS, and HC groups showed significant differences on 2 tests: letter fluency (table 2) and digit backward raw score, which is a measure of attention and working memory (see appendix e-1 for neuropsychological test results).

**Figure 1** Cerebral activation related to letter fluency performance



The main effect of the fMRI task (all subjects) is reported at a threshold of  $p < 0.05$  whole brain corrected for family-wise error. Regions (L = left, R = right) of activation include (Brodmann areas [BAs]): L middle frontal gyrus BAs 9 and 46; L inferior frontal gyrus BAs 45 and 47; R occipital lobe, lingual gyrus, BA 18; L cerebellum, posterior lobe; R occipital lobe, BA 17; L superior frontal gyrus BAs 6 and 8; L middle temporal gyrus BA 22; L cingulate gyrus, BA 24. The Montreal Neurological Institute (MNI) coordinates of the most medial part of the left frontal region are  $x = -33, y = 30, z = 0$ , which corresponds to the inferior frontal gyrus, BA 47. The MNI coordinates of the most medial part of the left frontal region are  $x = -33, y = 30, z = 0$ , which corresponds to the inferior frontal gyrus, BA 47.

**Performance in the scanner: Letter and category fluency.**

The mean number of words generated on the letter fluency task in the scanner differed among the PMA, ALS, and HC groups ( $F = 3.7; p < 0.05$ ); patients with PMA generated on average 38.2 (SD 12.5) words, patients with ALS generated 31.1 (10.8) words, and HCs generated 40.6 (11.3) words ( $p < 0.05$  for ALS vs HCs). Performance during the control condition (counting backward) did not differ significantly between groups.

The mean number of words generated on the category fluency task in the scanner was higher than that of the letter fluency task: patients with PMA generated 44.2 (14.1) words, patients with ALS generated 38.8 (10.2) words, and HCs generated 44.3 (11.0) words. This result indicates that the participants complied with the task instructions, because similar differences between letter and category fluency performance were found during neuropsychological testing outside the scanner, and have been reported in the literature.<sup>31</sup> Note that the neuropsychological examination and fMRI tasks differed in time durations regarding fluency, hampering a direct comparison.



**Cerebral activation related to letter fluency performance: BOLD activation.**

Whole-brain analysis of functional activation data across all participants showed letter fluency-related activation of left-sided brain regions, including inferior frontal, dorsal lateral prefrontal, anterior cingulate, and posterior temporal and bilateral occipital cortices (figure 1). The category fluency fMRI task showed robust left frontal and left (para) hippocampal activation ( $p < 0.05$  whole brain corrected for family-wise error), also as described before.<sup>26</sup>

**Between-group comparison of letter fluency-related cerebral activation.**

Between-group comparison of activation changes with performance as a covariate showed a significant difference of letter fluency BOLD activation among PMA, ALS, and HC groups in the left IFG (Brodmann area [BA] 45) (figure 2 and table 3). The BOLD activation in BA 45 of patients with PMA was lower compared to that of controls and higher compared to that of patients with ALS ( $p = 0.035; z$  score 4.11; cluster size = 11). Another cluster in the IFG (BA 9) showed a trend ( $z$  score 3.92;  $p = 0.069$ ; cluster size = 8) with lower activation in both PMA and ALS patients compared with HCs (table 3). Repeated analysis without performance as a covariate revealed similar results for the cluster in the left IFG (BA 45;  $z$  score 4.24;  $p = 0.022$ ; cluster size = 14). Repeated analysis with age and education as covariates (BA 45;  $z$  score 4.72;  $p = 0.003$ ; cluster size = 21) and adding the ARWMC and volume of the IFG (BA 45;  $z$  score 4.53;  $p = 0.008$ ; cluster size = 15) did not change the results. Excluding 5 familial cases (BA 45;  $z$  score 4.12;

**Figure 2** Between-group comparison of letter fluency-related cerebral activation: Region of interest analysis



Contrast estimates at the left inferior frontal gyrus (Montreal Neurological Institute coordinates:  $x = -48$ ,  $y = 36$ ,  $z = 6$ , Brodmann area 45;  $p = 0.035$ ;  $z$  score 4.11; cluster size = 11 voxels) for patients with PMA, patients with ALS, and healthy controls. Main effects of group are reported at  $p < 0.05$ , family-wise error-corrected for the extent of the composite mask with performance as covariate. ALS = amyotrophic lateral sclerosis; CI = confidence interval; PMA = progressive muscular atrophy.

$p = 0.036$ ; cluster size = 8) or 3 left-handed participants (BA 45;  $z$  score 4.03;  $p = 0.048$ ; cluster size = 11) revealed similar results (appendix e-2).

**Between-group comparison of category fluency BOLD activation.** Between-group comparisons did not show significant activation changes during category fluency.

Two small clusters in the left middle frontal gyrus (Montreal Neurological Institute coordinates:  $x = -24$ ,  $y = 21$ ,  $z = 57$ ; BA 6;  $z = 3.40$ ; cluster size = 3) and left parahippocampal gyrus ( $x = -33$ ,  $y = -33$ ,  $z = -12$ ; BA 36;  $z = 3.58$ ; cluster size = 3) did not survive FWE.

**Structural MRI: Regional brain volume and age-related white matter scores.** No differences were shown for mean volumes of the IFG scaled for total gray matter volumes, among patients with PMA and ALS and HCs ( $F = 2.3$ ;  $p = 0.112$ ). The ARWMC score did not show significant differences among the PMA, ALS, and HC groups (table 1).

**DISCUSSION** This study revealed cerebral activation abnormalities in MND patients with and without clinical signs of UMN involvement. A letter fluency task showed lower activation in the IFG of patients with PMA and ALS, which was most pronounced in patients with ALS. These results demonstrate that fMRI is a feasible and sensitive measure to detect nonmotor cerebral changes related to cognitive dysfunction in MND.<sup>6,32,33</sup>

Our finding of lower regional cerebral activation in PMA complements reduced fractional anisotropy in the prefrontal white matter on diffusion tensor imaging in 10 other patients with PMA in our earlier study.<sup>12</sup> A cerebral blood flow study (PET) during a joystick movement paradigm in patients with PMA did not show changes in the PFC, which may have been related to the task used and a relatively small sample ( $n = 5$ ).<sup>11</sup> Magnetic resonance spectroscopy showed a correlation between a reduced *N*-acetyl acetate/creatinine-phosphocreatinine ratio in the PFC and letter fluency performance in patients with ALS, but not in patients with PMA. Also in this study, a small sample size ( $n = 5$  patients with PMA) precluded firm conclusions.<sup>8</sup>

The neuropsychological assessment in the present study showed letter fluency impairment in patients with PMA, which is the most consistent cognitive abnormality in ALS and has likewise been described in limb-onset ALS patients and PMA patients.<sup>4,7,8,34</sup> The neuropsychological assessment further showed that the cognitive profile of patients with ALS was largely in agreement with that reported in the literature, including deficits on letter and category fluency, naming, and memory.<sup>1,6,7,13</sup> The present study thus demonstrates that nonmotor cerebral activation abnormalities (impaired recruitment of the left IFG) are linked to impairment on an important clinical measure of executive dysfunction in patients with PMA comparable to findings in patients with ALS.<sup>5,6</sup>

Cortical atrophy of the PFC, including the IFG, is a consistent imaging finding in ALS, in particular in patients with ALS–frontotemporal dementia.<sup>6,29,35</sup> The IFG contains BA 45 and showed lower activation in patients with MND in the present study, which is in agreement with fMRI findings in ALS patients without dementia by others.<sup>6</sup> BA 45 is designated as Broca area together with BA 44, and has been implicated in word retrieval.<sup>36</sup> A postmortem study

**Table 3** Comparison of letter fluency fMRI activation between groups

Contrast	k	Side	BA		MNI coordinates			F/t	z	P <sub>FWE</sub>
					x	y	z			
Effect of diagnosis	11	L	45	IFG	-48	36	6	F = 13.52	4.11	0.035 <sup>a</sup>
	8	L	9	IFG	-36	6	27	F = 12.30	3.92	0.069
PMA, ALS, HC	2	L	32	Ant Cing	-6	36	18	F = 8.52	3.22	0.484
PMA < HC	9	L	9	IFG	-33	6	27	t = 4.54	4.14	0.026 <sup>a</sup>
	19	L	32	Ant Cing	-6	36	18	t = 4.11	3.80	0.082
	3	L	45	IFG	-51	36	3	t = 3.89	3.62	0.143
ALS < HC	24	L	45	IFG	-48	36	6	t = 5.19	4.63	0.004 <sup>a</sup>
	13	L	9	IFG	-36	6	27	t = 3.97	3.69	0.118
	4	L	6	Mid Fr G	-33	6	51	t = 3.63	3.40	0.259

Abbreviations: ALS = amyotrophic lateral sclerosis; Ant Cing = anterior cingulate cortex; BA = Brodmann area; FWE = family-wise error; HC = healthy control; IFG = inferior frontal gyrus; k = number of voxels; Mid Fr G = middle frontal gyrus; MNI = Montreal Neurological Institute; PMA = progressive muscular atrophy.

Main effects of group and post hoc t tests are reported at  $p < 0.05$ , FWE-corrected for the extent of the composite mask with performance as covariate.

<sup>a</sup> Statistically significant values.

has shown pronounced pathologic changes in BAs 45 and 44 in patients with MND who have aphasia or dementia.<sup>37</sup> Together with evidence of language and semantic memory impairment in patients with MND who do not have dementia, this supports the notion that the left IFG is vulnerable to the pathologic process underlying the MND–frontotemporal dementia spectrum.<sup>6,7,35,38</sup>

Together with clinical, pathologic, and imaging evidence of corticospinal tract changes in PMA, the impaired prefrontal activation as shown in the present study argues against the view of PMA and ALS being separate diseases.<sup>11,14,16</sup> Therefore, the current diagnostic criteria for MND, which are based on the presence of UMN signs and actually exclude PMA, may need to be reconsidered.<sup>17</sup>

Several methodologic issues of the present study warrant consideration. First, dysarthria may result in overestimation of fluency impairment. Three features argue against such a bias: (1) none of our patients with PMA had bulbar onset, (2) 4 patients with PMA had only slight bulbar involvement, which did not affect fluency testing (an exploratory analysis showed that their demographically corrected fluency scores were normal; percentile range: 21–70); and (3) we used a covert fluency fMRI task, minimizing orofacial movements in the scanner.

Second, because of careful matching of PMA patients with ALS patients and HC subjects, and the results of the analyses of covariance, we think it is unlikely that the impaired prefrontal activation is related to depression, anxiety, age, education, or white matter changes.

Furthermore, impaired IFG activation in the present study is unlikely to result from noncompliance because (1) the use of fluency performance as

a covariate did not substantially alter the results, (2) performance of the control condition (counting backward) in the scanner did not differ between groups, and (3) differences between performance on letter and category fluency tasks (higher scores for category) in the scanner are compatible with that in the neuropsychological investigation outside the scanner in our study, and similar differences have been reported in our earlier work and the literature.<sup>26</sup>

Some potential limitations of this study should be noted. First, patient samples are relatively small and we obtained some trend-significant results on neuropsychological and fMRI analyses, suggesting that more power is needed to establish the nonmotor cerebral involvement of PMA in more detail. Second, although disease duration of patients with PMA was limited to 5 years, the remaining heterogeneity within the PMA cohort may have obscured fMRI changes.

Our results indicate impaired prefrontal activation related to fluency deficits in patients with MND regardless of UMN signs. Future studies should examine patients with PMA at an early disease stage to assess whether nonmotor changes have an impact on treatment issues, patient-caregiver interaction, and survival duration, similar to ALS.<sup>2,39,40</sup> Also, studies on nonmotor changes in MND should include measures of UMN severity in addition to the ALSFRS-R (which is mostly a lower motor neuron measure) to further confirm the hypothesis that a proportion of patients with PMA may be viewed as having ALS minus detectable UMN signs.

#### AUTHOR CONTRIBUTIONS

Dr. Raaphorst: drafting the manuscript for content, study design, analysis and interpretation of the data, acquisition of the data, statistical analysis, and study coordination. M.-J. van Tol: revising the manuscript for

content, study design, analysis and interpretation of the data, acquisition of the data, statistical analysis. P. Groot: analysis and interpretation of the data. E. Altena and Y. van der Werf: revising the manuscript for content, study design. Dr. Majoie: revising the manuscript for content, analysis and acquisition of the data, study design. Dr. van der Kooij and Dr. van den Berg: revising the manuscript for content, acquisition of the data. B. Schmand: revising the manuscript for content, interpretation of the data, study supervision. Dr. de Visser and Dr. Veltman: revising the manuscript for content, study design, interpretation of the data, study supervision.

## ACKNOWLEDGMENT

The authors thank Hepke Grupstra, Hanneke Börger, and Inge van Beilen for their help with the recruitment of the patients and Johan van der Meer and Aart Nederveen for technical assistance. They thank the patients and their partners for their participation and the staff of many neurology and rehabilitation outpatient clinics in the Netherlands for their hospitality.

## STUDY FUNDING

The Amsterdam Brain Imaging Platform supported this study.

## DISCLOSURE

The authors report no disclosures relevant to the manuscript. Go to [Neurology.org](http://Neurology.org) for full disclosures.

*Received February 13, 2014. Accepted in final form May 17, 2014.*

## REFERENCES

1. Phukan J, Elamin M, Bede P, et al. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. *J Neurol Neurosurg Psychiatry* 2012;83:102–108.
2. Olney RK, Murphy J, Forshe D, et al. The effects of executive and behavioral dysfunction on the course of ALS. *Neurology* 2005;65:1774–1777.
3. Chiò A, Ilardi A, Cammarosano S, Moglia C, Montuschi A, Calvo A. Neurobehavioral dysfunction in ALS has a negative effect on outcome and use of PEG and NIV. *Neurology* 2012;78:1085–1089.
4. Goldstein LH, Abrahams S. Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment. *Lancet Neurol* 2013;12:368–380.
5. Abrahams S, Goldstein LH, Kew JJ, et al. Frontal lobe dysfunction in amyotrophic lateral sclerosis: a PET study. *Brain* 1996;119:2105–2120.
6. Abrahams S, Goldstein LH, Simmons A, et al. Word retrieval in amyotrophic lateral sclerosis: a functional magnetic resonance imaging study. *Brain* 2004;127:1507–1517.
7. Raaphorst J, de Visser M, Linssen WH, de Haan RJ, Schmand B. The cognitive profile of amyotrophic lateral sclerosis: a meta-analysis. *Amyotroph Lateral Scler* 2010;11:27–37.
8. Quinn C, Elman L, McCluskey L, et al. Frontal lobe abnormalities on MRS correlate with poor letter fluency in ALS. *Neurology* 2012;79:583–588.
9. Abrahams S, Goldstein LH, Suckling J, et al. Frontotemporal white matter changes in amyotrophic lateral sclerosis. *J Neurol* 2005;252:321–331.
10. Wicks P, Abrahams S, Leigh PN, Williams T, Goldstein LH. Absence of cognitive, behavioral, or emotional dysfunction in progressive muscular atrophy. *Neurology* 2006;67:1718–1719.
11. Kew JJ, Brooks DJ, Passingham RE, Rothwell JC, Frackowiak RS, Leigh PN. Cortical function in progressive lower motor neuron disorders and amyotrophic lateral sclerosis: a comparative PET study. *Neurology* 1994;44:1101–1110.
12. van der Graaff MM, Sage CA, Caan MW, et al. Upper and extra-motoneuron involvement in early motoneuron disease: a diffusion tensor imaging study. *Brain* 2011;134:1211–1228.
13. Raaphorst J, de Visser M, van Tol MJ, et al. Cognitive dysfunction in lower motor neuron disease: executive and memory deficits in progressive muscular atrophy. *J Neurol Neurosurg Psychiatry* 2011;82:170–175.
14. Visser J, van den Berg-Vos RM, Franssen H, et al. Disease course and prognostic factors of progressive muscular atrophy. *Arch Neurol* 2007;64:522–528.
15. Cervenakova L, Protas II, Hirano A, et al. Progressive muscular atrophy variant of familial amyotrophic lateral sclerosis (PMA/ALS). *J Neurol Sci* 2000;177:124–130.
16. Ince PG, Evans J, Knopp M, et al. Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS. *Neurology* 2003;60:1252–1258.
17. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Other Motor Neuron Disord* 2000;1:293–299.
18. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. *Neurology* 1998;51:1546–1554.
19. Desmond JE, Glover GH. Estimating sample size in functional MRI (fMRI) neuroimaging studies: statistical power analyses. *J Neurosci Methods* 2002;118:115–128.
20. Thirion B, Pinel P, Mériaux S, Roche A, Dehaene S, Poline JB. Analysis of a large fMRI cohort: statistical and methodological issues for group analyses. *Neuroimage* 2007;35:105–120.
21. Cedarbaum JM, Stambler N. Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFERS) in multicenter clinical trials. *J Neurol Sci* 1997;152(suppl 1):S1–S9.
22. Ellis CM, Simmons A, Andrews C, Dawson JM, Williams SC, Leigh PN. A proton magnetic resonance spectroscopic study in ALS: correlation with clinical findings. *Neurology* 1998;51:1104–1109.
23. Benton A, Hamsher K, Sivan A. *Multilingual Aphasia Examination*, 3rd ed. Iowa City: AJA Publishers; 1983.
24. Luteijn F, Barelds DPH. *Groningen Intelligence Test 2 (git2): Manual*. Amsterdam: Harcourt Test Publishers; 2004.
25. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. *Acta Psychiatr Scand* 1983;67:361–370.
26. Altena E, van der Werf YD, Sanz-Arigita EJ, et al. Prefrontal hypoactivation and recovery in insomnia. *Sleep* 2008;31:1271–1276.
27. Schmand B, Groenink SC, van den Dungen M. Letter fluency: psychometric properties and Dutch normative data [in Dutch]. *Tijdschr Gerontol Geriatr* 2008;39:64–76.
28. Van Overschelde JP, Rawson KA, Dunlosky J. Category norms: an updated and expanded version of the norms. *J Mem Lang* 2004;50:289–335.
29. Kew JJ, Goldstein LH, Leigh PN, et al. The relationship between abnormalities of cognitive function and cerebral activation in amyotrophic lateral sclerosis: a neuropsychological and positron emission tomography study. *Brain* 1993;116:1399–1423.
30. WFU PickAtlas Toolbox. Available at: <http://www.ansir.wfubmc.edu>. Accessed April 22, 2014.

31. Strauss E, Sherman E, Spreen O. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. New York: Oxford University Press; 2006.
32. Mohammadi B, Kollwe K, Samii A, Dengler R, Münte TF. Functional neuroimaging at different disease stages reveals distinct phases of neuroplastic changes in amyotrophic lateral sclerosis. *Hum Brain Mapp* 2011;32:750–758.
33. Lulé D, Ludolph AC, Kassubek J. MRI-based functional neuroimaging in ALS: an update. *Amyotroph Lateral Scler* 2009;10:258–268.
34. Rottig D, Leplow B, Eger K, Ludolph AC, Graf M, Zierz S. Only subtle cognitive deficits in non-bulbar amyotrophic lateral sclerosis patients. *J Neurol* 2006;253:333–339.
35. Grossman M, Anderson C, Khan A, Avants B, Elman L, McCluskey L. Impaired action knowledge in amyotrophic lateral sclerosis. *Neurology* 2008;71:1396–1401.
36. Horwitz B, Amunts K, Bhattacharyya R, et al. Activation of Broca's area during the production of spoken and signed language: a combined cytoarchitectonic mapping and PET analysis. *Neuropsychologia* 2003;41:1868–1876.
37. Bak TH, O'Donovan DG, Xuereb JH, Boniface S, Hodges JR. Selective impairment of verb processing associated with pathological changes in Brodmann areas 44 and 45 in the motor neurone disease-dementia-aphasia syndrome. *Brain* 2001;124:103–120.
38. Rakowicz WP, Hodges JR. Dementia and aphasia in motor neuron disease: an underrecognised association? *J Neurol Neurosurg Psychiatry* 1998;65:881–889.
39. Elamin M, Phukan J, Bede P, et al. Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. *Neurology* 2011;76:1263–1269.
40. Chiò A, Vignola A, Mastro E, et al. Neurobehavioral symptoms in ALS are negatively related to caregivers' burden and quality of life. *Eur J Neurol* 2010;17:1298–1303.

## 2014 AAN Annual Meeting On Demand

Take the meeting with you. AAN Annual Meeting On Demand is the comprehensive digital library of presentations from the 2014 Annual Meeting providing more than 500 hours\* of educational content.

**Order now at [AANonDemand.com](http://AANonDemand.com)**

*\*Total hours of presentations available subject to speaker permissions.*

## New *Neurology Compensation and Productivity Report*: How Do You Compare?

The AAN's *2014 Neurology Compensation and Productivity Report* is now available. Based on data from hundreds of neurologists and neurology practice managers, this is the most recent and reliable information on the neurology profession.

The *Neurology Compensation and Productivity Report* is a powerful, versatile tool that can help you:

- Compare your salary, productivity, and practice characteristics to your peers—and use this information in contract negotiations
- Evaluate physician performance compared to your peers
- Discover fair-market value based on customizable filters such as your subspecialty, region, and practice type
- Analyze whether it makes sense to expand your practice
- Identify variances in key metrics for use in practice improvements

Learn more at [AAN.com/view/2014NeuroReport](http://AAN.com/view/2014NeuroReport).

# Neurology<sup>®</sup>

## **Prefrontal involvement related to cognitive impairment in progressive muscular atrophy**

Joost Raaphorst, Marie-José van Tol, Paul F.C. Groot, et al.  
*Neurology* 2014;83;818-825 Published Online before print July 30, 2014  
DOI 10.1212/WNL.0000000000000745

**This information is current as of July 30, 2014**

<b>Updated Information &amp; Services</b>	including high resolution figures, can be found at: <a href="http://www.neurology.org/content/83/9/818.full.html">http://www.neurology.org/content/83/9/818.full.html</a>
<b>Supplementary Material</b>	Supplementary material can be found at: <a href="http://www.neurology.org/content/suppl/2014/07/30/WNL.0000000000000745.DC1.html">http://www.neurology.org/content/suppl/2014/07/30/WNL.0000000000000745.DC1.html</a>
<b>References</b>	This article cites 36 articles, 18 of which you can access for free at: <a href="http://www.neurology.org/content/83/9/818.full.html##ref-list-1">http://www.neurology.org/content/83/9/818.full.html##ref-list-1</a>
<b>Subspecialty Collections</b>	This article, along with others on similar topics, appears in the following collection(s): <b>Amyotrophic lateral sclerosis</b> <a href="http://www.neurology.org/cgi/collection/amyotrophic_lateral_sclerosis">http://www.neurology.org/cgi/collection/amyotrophic_lateral_sclerosis</a> <b>Executive function</b> <a href="http://www.neurology.org/cgi/collection/executive_function">http://www.neurology.org/cgi/collection/executive_function</a> <b>fMRI</b> <a href="http://www.neurology.org/cgi/collection/fmri">http://www.neurology.org/cgi/collection/fmri</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/misc/about.xhtml#permissions">http://www.neurology.org/misc/about.xhtml#permissions</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://www.neurology.org/misc/addir.xhtml#reprintsus">http://www.neurology.org/misc/addir.xhtml#reprintsus</a>

*Neurology*® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2014 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

